These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 8639850)

  • 1. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
    Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
    Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
    Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD
    Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission.
    Guerrasio A; Rosso C; Martinelli G; Lo Coco F; Pampinella M; Santoro A; Lanza C; Allione B; Resegotti L; Saglio G
    Br J Haematol; 1995 Jun; 90(2):364-8. PubMed ID: 7794758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
    Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
    Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
    Kwong YL; Chan V; Wong KF; Chan TK
    Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
    Tobal K; Yin JA
    Blood; 1996 Nov; 88(10):3704-9. PubMed ID: 8916934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia.
    Miyamoto T; Nagafuji K; Harada M; Eto T; Fujisaki T; Kubota A; Akashi K; Mizuno S; Takenaka K; Kanaji T
    Br J Haematol; 1995 Sep; 91(1):132-8. PubMed ID: 7577620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
    Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
    Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Harada M; Niho Y
    Leuk Lymphoma; 1997 Mar; 25(1-2):69-75. PubMed ID: 9130615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears.
    Tsukamoto N; Karasawa M; Tanaka Y; Yokohama A; Uchiumi H; Matsushima T; Murakami H; Nojima Y
    Int J Hematol; 2003 Nov; 78(4):362-9. PubMed ID: 14686496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.
    Era T; Asou N; Kunisada T; Yamasaki H; Asou H; Kamada N; Nishikawa S; Yamaguchi K; Takatsuki K
    Genes Chromosomes Cancer; 1995 May; 13(1):25-33. PubMed ID: 7541640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
    Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
    Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
    Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
    Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
    Miyamoto T; Weissman IL; Akashi K
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7521-6. PubMed ID: 10861016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
    Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
    Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
    Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
    Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.